- Home
- LEXX vs AEON Comparison
LEXX vs AEON Comparison
Compare LEXX & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEXX
- AEON
- Stock Information
- Founded
- LEXX 2004
- AEON N/A
- Country
- LEXX Canada
- AEON United States
- Employees
- LEXX N/A
- AEON N/A
- Industry
- LEXX Biotechnology: Pharmaceutical Preparations
- AEON Biotechnology: Pharmaceutical Preparations
- Sector
- LEXX Health Care
- AEON Health Care
- Exchange
- LEXX Nasdaq
- AEON Nasdaq
- Market Cap
- LEXX 43.5M
- AEON 36.4M
- IPO Year
- LEXX N/A
- AEON N/A
- Fundamental
- Price
- LEXX $2.01
- AEON $0.61
- Analyst Decision
- LEXX Strong Buy
- AEON Strong Buy
- Analyst Count
- LEXX 2
- AEON 1
- Target Price
- LEXX $11.00
- AEON $5.00
- AVG Volume (30 Days)
- LEXX 148.5K
- AEON 106.3K
- Earning Date
- LEXX 01-10-2025
- AEON 11-13-2024
- Dividend Yield
- LEXX N/A
- AEON N/A
- EPS Growth
- LEXX N/A
- AEON N/A
- EPS
- LEXX N/A
- AEON N/A
- Revenue
- LEXX $411,019.00
- AEON N/A
- Revenue This Year
- LEXX $82.02
- AEON N/A
- Revenue Next Year
- LEXX $95.09
- AEON N/A
- P/E Ratio
- LEXX N/A
- AEON N/A
- Revenue Growth
- LEXX 34.05
- AEON N/A
- 52 Week Low
- LEXX $1.20
- AEON $0.60
- 52 Week High
- LEXX $6.85
- AEON $17.17
- Technical
- Relative Strength Index (RSI)
- LEXX 26.93
- AEON 28.55
- Support Level
- LEXX $2.20
- AEON $0.60
- Resistance Level
- LEXX $2.42
- AEON $0.88
- Average True Range (ATR)
- LEXX 0.19
- AEON 0.07
- MACD
- LEXX -0.00
- AEON -0.03
- Stochastic Oscillator
- LEXX 7.27
- AEON 2.62
About LEXX Lexaria Bioscience Corp.
Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. The Company has four reportable segments: Intellectual Property Licensing, B2B Production, Research and Development and Corporate. It earns maximum revenue from Intellectual Property Licensing.
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.